Melanoma
Carlo Riccardo Rossi
Melanoma and Sarcoma Unit, Veneto Institute of Oncology IOV, IRCCS, Padova, Italy
Search for more papers by this authorAntonio Sommariva
Melanoma and Sarcoma Unit, Veneto Institute of Oncology IOV, IRCCS, Padova, Italy
Search for more papers by this authorCarlo Riccardo Rossi
Melanoma and Sarcoma Unit, Veneto Institute of Oncology IOV, IRCCS, Padova, Italy
Search for more papers by this authorAntonio Sommariva
Melanoma and Sarcoma Unit, Veneto Institute of Oncology IOV, IRCCS, Padova, Italy
Search for more papers by this authorRoss D. Farhadieh BSc(Med)Hons, MBBS, MD, EBOPRASF, FRACS(Plast), FRCS(Plast)
Panthea Plastic Surgery Clinics, Sydney and Canberra, Australia and Australian National University, Canberra, Australia
Search for more papers by this authorNeil W. Bulstrode BSc(Med)Hons, MBBS, MD, FRCS(Plast)
Clinical Lead Plastic Surgery
Great Ormond Street Hospital, London, UK
Search for more papers by this authorSabrina Cugno MD, MSc, FRCSC
Assistant Professor
McGill University, Department of Plastic Surgery, Montreal Children's Hospital, Montreal, Canada
Search for more papers by this authorSummary
Melanoma has shown a consistent increase of incidence resulting from an unidentified interaction between inherited factors combined with environmental factors, mainly solar ultraviolet radiations. Surgery represents the standard treatment for primary melanoma and guarantees an optimal locoregional control in the presence of lymph nodes metastasis. Sentinel lymph node biopsy is a promising procedure for risk stratification, but its impact on patient survival remains under study. The discovery of new drugs (ipilimumab and vemurafenib) with an encouraging clinical activity against metastatic melanoma opens new horizons in the treatment of metastatic melanoma. Despite the continuous improvement in target therapy the response rate and the durability of clinical response remains poor and further studies are needed.
References
- MacKie RM, Hauschild A, Eggermont AM. Epidemiology of invasive cutaneous melanoma. Annals of Oncology 2009; 20(Suppl. 6): vi1–7.
- Russak JE, Rigel DS. Risk factors for the development of primary cutaneous melanoma. Dermatologic Clinics 2012; 30: 363–368.
- Ibrahim N, Haluska FG. Molecular pathogenesis of cutaneous melanocytic neoplasms. Annual Review of Pathology 2009; 4: 551–579.
- Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Annals of Surgery 1970; 172: 902–908.
- Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. Journal of Clinical Oncology 2009; 27: 6199–206.
- Forschner A, Eigentler TK, Pflugfelder A, et al. Melanoma staging: facts and controversies. Clinics in Dermatology 2010; 28: 275–280.
- Xing Y, Bronstein Y, Ross MI, et al. Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. Journal of the National Cancer Institute 2011; 103: 129–142.
- Sladden MJ, Balch C, Barzilai DA, et al. Surgical excision margins for primary cutaneous melanoma. Cochrane Database of Systematic Reviews 2009: CD004835.
- Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. New England Journal of Medicine 2006; 355: 1307–1317.
- Wong SL, Balch CM, Hurley P, et al. Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. Journal of Clinical Oncology 2012; 30: 2912–2918.
-
Spratt J. Groin dissection. Journal of Surgical Oncology 2000; 73: 243–62.
10.1002/(SICI)1096-9098(200004)73:4<243::AID-JSO13>3.0.CO;2-W CAS PubMed Web of Science® Google Scholar
- Chang SB, Askew RL, Xing Y, et al. Prospective assessment of postoperative complications and associated costs following inguinal lymph node dissection (ILND) in melanoma patients. Annals of Surgical Oncology 2010; 17: 2764–2772.
- Delman KA, Kooby DA, Ogan K, Hsiao W, Master V. Feasibility of a novel approach to inguinal lymphadenectomy: minimally invasive groin dissection for melanoma. Annals of Surgical Oncology 2010; 17: 731–737.
- Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. Journal of Clinical Oncology 2001; 19: 3635–3648.
- Rossi CR, Mocellin S, Pasquali S, Pilati P, Nitti D. N-ratio: a novel independent prognostic factor for patients with stage-III cutaneous melanoma. Annals of Surgical Oncology 2008; 15: 310–315.
- Bilimoria KY, Raval MV, Bentrem DJ, Wayne JD, Balch CM, Ko CY. National assessment of melanoma care using formally developed quality indicators. Journal of Clinical Oncology 2009; 27: 5445–5451.
- Mocellin S, Lens MB, Pasquali S, Pilati P, Chiarion Sileni V. Interferon alpha for the adjuvant treatment of cutaneous melanoma. Cochrane Database of Systematic Reviews 2013; 6: CD008955.
- Burmeister BH, Henderson MA, Ainslie J, et al. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncology 2012; 13: 589–597.
- Kroon BB, Noorda EM, Vrouenraets BC, van Slooten GW, Nieweg OE. Isolated limb perfusion for melanoma. Surgical Oncology Clinics of North America 2008; 17: 785–794, viii–ix.
- Kroon HM, Thompson JF. Isolated limb infusion: a review. Journal of Surgical Oncology 2009; 100: 169–177.
- Mir LM GJ, Sersa G, Collins CG Standard operating procedures of the electrochemotherapy: instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the Cliniporator (TM) by means of invasive or non-invasive electrodes. EJC Supplements 2006: 14–25.
- Ollila DW. Complete metastasectomy in patients with stage IV metastatic melanoma. Lancet Oncology 2006; 7: 919–924.
- Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. New England Journal of Medicine 2010; 363: 711–723.
- Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. New England Journal of Medicine 2011; 364: 2507–2516.
- The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28. Archives of Ophthalmology 2006; 124: 1684–1693.
- Onken MD, Worley LA, Tuscan MD, Harbour JW. An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma. Journal of Molecular Diagnostics 2010; 12: 461–468.
- Patrick RJ, Fenske NA, Messina JL. Primary mucosal melanoma. Journal of the American Academy of Dermatology 2007; 56: 828–834.
- Minor DR, Kashani-Sabet M, Garrido M, et al. Sunitinib therapy for melanoma patients with KIT mutations. Clinical Cancer Research 2012; 18: 1457–1463.
